Comments
TCG Lifesciences, part of New York based Chatterjee Group, has received approval from the US Food and Drug Administration (USFDA) for its chemical development and manufacturing facility in Hyderabad.
Supported by a strong talent pool of over 800 qualified scientists of TCG Lifesciences, Clininvent Research Pvt. Ltd., the 100 per cent subsidiary of the company, has successfully passed a pre-approval inspection as a manufacturing plant, by the US regulator, according to a release.
Located at Aanataram near here, the facility manufactures advanced intermediates and Regulatory Starting Materials (RSMs) and custom manufacturing of New Chemical Entities (NCEs).
“This marks our entry into the high growth generic APIs and intermediates domain for regulated markets,’’ Swapan Bhattacharya, Managing Director, TCG Lifesciences said.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.